Clinical Trial Update: Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for the Treatment of Untreated Indolent B-Cell Non-Hodgkin Lymphoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating mosunetuzumab with or without polatuzumab vedotin and obinutuzumab for untreated indolent B-cell non-Hodgkin lymphoma has co…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
• Follicular Lymphoma
• Follicular Lymphoma Grade 3a
• Indolent B-cell Non-hodgkin Lymphoma
• Marginal Zone Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• Mosunetuzumab (mosunetuzumab)
• Obinutuzumab (obinutuzumab)
• polatuzumab vedotin (polatuzumab vedotin)

Snippet

Sponsor: University of Washington | Conditions: Non-Hodgkin Lymphoma, Grade 1 Follicular Lymphoma | Phase 2 | Status: COMPLETED